Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01076270 · OUTCOME

CD34-positive Cells Collected

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · Source last updated 2017-06-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
CD34-positive cells collected/kg
Interval / dispersion
Not reported
Time frame
At the end of apheresis for cell collection

What was measured

Number of CD34-positive cells collected per kg recipient body weight

Analysis population: Trial terminated; only one patient enrolled

Groups in this outcome

Filgrastim and Plerixafor for PBSC Mobilization

Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells. After completion of study treatment, donors are followed up 1 day after the last stem cell donation. plerixafor: Given SC filgrastim: Given SC peripheral blood stem cell transplantation: Infusion of peripheral blood stem cells allogeneic hematopoietic stem cell transplantation: Infusion of hematopoietic stem cells

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Filgrastim and Plerixafor for PBSC Mobilization1

Reported measurements

Source class 1
Values in CD34-positive cells collected/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Filgrastim and Plerixafor for PBSC Mobilization4,760,000Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        4,760,000
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    units
    Participants
description
Number of CD34-positive cells collected per kg recipient body weight
groups
  1. description
    Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells. After completion of study treatment, donors are followed up 1 day after the last stem cell donation. plerixafor: Given SC filgrastim: Given SC peripheral blood stem cell transplantation: Infusion of peripheral blood stem cells allogeneic hematopoietic stem cell transplantation: Infusion of hematopoietic stem cells
    id
    OG000
    title
    Filgrastim and Plerixafor for PBSC Mobilization
param Type
NUMBER
population Description
Trial terminated; only one patient enrolled
reporting Status
POSTED
time Frame
At the end of apheresis for cell collection
title
CD34-positive Cells Collected
type
SECONDARY
unit Of Measure
CD34-positive cells collected/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice